Table 1.

Diagnostic criteria and prevalence for hyperuricemia in each country/area

Country/area	Male	Female	General	Prevalence
United States	7.0 mg/dL (420 µmol/L)	6.0 mg/dL (360 µmol/L)	7.0 mg/dL (420 µmol/L)	21%35
Japan	7.0 mg/dL (420 µmol/L)	6.0 mg/dL (360 µmol/L)	/	30% in male and 3% in female440
United Kingdom	6.8 mg/dL (404 µmol/L)	6.0 mg/dL (360 µmol/L)	/	27.72% in male and 10.69% in female336
India	/	/	7.0 mg/dL (420 µmol/L)	44.6%48
European Union	6.8 mg/dL (404 µmol/L)	5.7 mg/dL (339 µmol/L)	/	11.9%–25.0% of the European population336
China	7.0 mg/dl (420.0 μmol/l)	6.0 mg/dl (360.0 μmol/l)	7.0 mg/dL (420 µmol/L)	17.7%54
Australia	/	/	7.0 mg/dL (420 µmol/L)	16.6%36
Finland	6.8 mg/dL (404 µmol/L)	5.7 mg/dL (339 µmol/L)	/	48.0% (60% in male and 31% in female)37
New Zealand	/	/	7.0 mg/dL (420 µmol/L)	17.0% (27.8% in male and 8.8% in female)38
Ireland	6.8 mg/dL (404 µmol/L)	5.7 mg/dL (339 µmol/L)	/	24.5% (25.0% in male and 24.1% in female)39
Croatia	6.8 mg/dL (404 µmol/L)	5.7 mg/dL (339 µmol/L)	/	9.9%40
Russia	/	/	7.0 mg/dL (420 µmol/L)	16.8%41
Turkey	7.0 mg/dl (420.0 μmol/l)	6.0 mg/dl (360.0 μmol/l)	7.0 mg/dL (420 µmol/L)	12.1% (19.0% in male and 5.8% in female)42
Qatar	/	/	7.0 mg/dL (420 µmol/L)	21.2%43
Korea	7.0 mg/dl (420.0 μmol/l)	6.0 mg/dl (360.0 μmol/l)	7.0 mg/dL (420 µmol/L)	11.4% (17.0% in male and 5.9% in female)44
Mexico	/	/	7.0 mg/dL (420 µmol/L)	20.6%45
Niger	/	/	7.0 mg/dL (420 µmol/L)	17.2%46
French Polynesia	/	/	6.0 mg/dL (360 µmol/L)	71.6%47
Jordan	/	/	7.0 mg/dL (420 µmol/L)	28.1%49
sub-Saharan African	/	/	6.0 mg/dL (360 µmol/L)	31.8%50
Thailand	7.0 mg/dl (420.0 μmol/l)	6.0 mg/dl (360.0 μmol/l)	7.0 mg/dL (420 µmol/L)	10.6% (18.4% in male and 7.8% in female)51
Saudi Arabia	7.0 mg/dL (420 µmol/L)	6.0 mg/dL (360 µmol/L)	7.0 mg/dL (420 µmol/L)	8.4%52
Bangladesh	7.0 mg/dl (420.0 μmol/l)	6.0 mg/dl (360.0 μmol/l)	7.0 mg/dL (420 µmol/L)	9.3%53

/, the country without an exact criteria